Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Rifaximin has no effect on hemodynamics in decompensated cirrhosis - A randomized, double blind, placebo controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Letter to the Editor: Glucocorticosteroids for Alcohol-Associated Hepatitis

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. PNPLA3 genotype and risk of liver and all-cause mortality

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  4. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND AND RATIONALE: Decompensated cirrhosis is characterized by disturbed systemic and splanchnic hemodynamics. Bacterial translocation from the gut is considered the key driver in this process. Intestinal decontamination with rifaximin may improve hemodynamics. This double-blind, randomized, controlled trial investigates the effects of rifaximin on hemodynamics, renal function and vasoactive hormones.

METHODS: We randomized 54 stable out-patients with cirrhosis and ascites to rifaximin 550 mg BD (n=36) or placebo BD (n=18). Forty-five patients were male, mean age 56 years (±8.4), the average Child score 8.3 (±1.3), and the MELD score 11.7 (±3.9). Measurements of hepatic venous pressure gradient (HVPG), cardiac output, and systemic vascular resistance (SVR) were performed at baseline and after 4 weeks. The glomerular filtration rate (GFR), plasma renin, noradrenaline, lipo-polysaccharide binding protein (LBP), troponin T and brain natriuretic peptide levels were measured.

RESULTS: Rifaximin had no effect on HVPG, mean 16.8 ±3.8 mmHg at baseline vs. 16.6 ±5.3 mmHg at follow-up compared to the placebo, mean 16.4 ±4 mmHg at baseline vs. 16.3 ±4.4 mmHg at follow-up, p=0.94. No effect was found on the cardiac output, mean 6.9 ±1.7 l/min at baseline vs. 6.9 ±2.3 l/min at follow-up compared to the placebo, mean 6.6 ±1.9 l/min at baseline compared to 6.5 ±2.1 l/min at follow-up, p=0.66. No effects on the GFR p=0.14 or the vasoactive hormones were found. Subgroup analyses on patients with increased LBP and SVR below the mean (1011 dynes x s/cm(5) ) revealed no effect of rifaximin.

CONCLUSIONS: Four weeks of treatment with rifaximin did not reduce the HVPG or improve systemic hemodynamics in patients with cirrhosis and ascites. Rifaximin did not affect GFR or levels of vasoactive hormones. ClinicalTrials.gov (NCT01769040). This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftHepatology (Baltimore, Md.)
Vol/bind65
Udgave nummer2
Sider (fra-til)592-603
ISSN0270-9139
DOI
StatusUdgivet - feb. 2017

ID: 49164086